All Stories

  1. Progression of lymphatic filariasis antigenaemia and microfilaraemia over 4.5 years in antigen-positive individuals, Samoa 2019-2023
  2. Laboratory Comparison of Rapid Antigen Diagnostic Tests for Lymphatic Filariasis: STANDARD Q Filariasis Antigen Test (QFAT) Versus Bioline Filariasis Test Strip (FTS)
  3. Epidemiology of Lymphatic Filariasis Antigen and Microfilaria in Samoa, 2019: 7–9 Months Post Triple-Drug Mass Drug Administration
  4. Molecular xenomonitoring as an indicator of microfilaraemia prevalence for lymphatic filariasis in Samoa in 2019
  5. Lymphatic filariasis antigen and microfilaria epidemiology in Samoa in 2019, six months post triple-drug mass drug administration
  6. Field laboratory comparison of STANDARD Q Filariasis Antigen Test (QFAT) with Bioline Filariasis Test Strip (FTS) for the detection of Lymphatic Filariasis in Samoa, 2023
  7. Ongoing transmission of lymphatic filariasis in Samoa 4.5 years after one round of triple-drug mass drug administration
  8. Molecular xenomonitoring as an indicator of microfilaraemia prevalence for lymphatic filariasis in Samoa in 2019
  9. Field comparison of STANDARD™ Q Filariasis Antigen Test (QFAT) with Bioline Filariasis Test Strip (FTS) for the detection of Lymphatic Filariasis in Samoa, 2023
  10. Laboratory Comparison of Rapid Antigen Diagnostic Tests for Lymphatic Filariasis: STANDARDTMQ Filariasis Antigen Test (QFAT) and Bioline Filariasis Test Strip (FTS)
  11. Persons ‘never treated’ in mass drug administration for lymphatic filariasis: identifying programmatic and research needs from a series of research review meetings 2020–2021
  12. Scabies prevalence after ivermectin-based mass drug administration for lymphatic filariasis, Samoa 2018–2019
  13. Spatial predictive risk mapping of lymphatic filariasis residual hotspots in American Samoa using demographic and environmental factors
  14. Lymphatic filariasis endgame strategies: Using GEOFIL to model mass drug administration and targeted surveillance and treatment strategies in American Samoa
  15. Predictive risk mapping of lymphatic filariasis residual hotspots in American Samoa using demographic and environmental factors
  16. Modelling lymphatic filariasis elimination in American Samoa: GEOFIL predicts need for new targets and six rounds of mass drug administration
  17. Evaluating Molecular Xenomonitoring as a Tool for Lymphatic Filariasis Surveillance in Samoa, 2018–2019
  18. Evaluating Molecular Xenomonitoring as a Tool for Lymphatic Filariasis Surveillance in Samoa, 2018-2019
  19. Bayesian Network Analysis of Lymphatic Filariasis Serology from Myanmar Shows Benefit of Adding Antibody Testing to Post-MDA Surveillance
  20. Potential use of antibodies to provide an earlier indication of lymphatic filariasis resurgence in post–mass drug ad ministration surveillance in American Samoa
  21. Lymphatic filariasis in 2016 in American Samoa: Identifying clustering and hotspots using non-spatial and three spatial analytical methods
  22. Potential use of antibodies to provide an earlier indication of lymphatic filariasis resurgence in post-mass drug administration surveillance, American Samoa
  23. Comparison of Immunochromatographic Test (ICT) and Filariasis Test Strip (FTS) for Detecting Lymphatic Filariasis Antigen in American Samoa, 2016
  24. Triple-Drug Treatment Is Effective for Lymphatic Filariasis Microfilaria Clearance in Samoa
  25. Triple-Drug Mass Drug Administration is Effective for Lymphatic Filariasis Microfilaria Clearance in Samoa
  26. Genetic epidemiology of lymphatic filariasis in American Samoa after mass drug administration
  27. Risk factors for lymphatic filariasis and mass drug administration non-participation in Mandalay Region, Myanmar
  28. Control and elimination of lymphatic filariasis in Oceania: Prevalence, geographical distribution, mass drug administration, and surveillance in Samoa, 1998–2017
  29. Potential strategies for strengthening surveillance of lymphatic filariasis in American Samoa after mass drug administration: Reducing ‘number needed to test’ by targeting older age groups, hotspots, and household members of infected persons
  30. Lymphatic filariasis epidemiology in Samoa in 2018: Geographic clustering and higher antigen prevalence in older age groups
  31. A community survey of coverage and adverse events following country-wide triple-drug mass drug administration for lymphatic filariasis elimination, Samoa 2018
  32. Supporting elimination of lymphatic filariasis in Samoa by predicting locations of residual infection using machine learning and geostatistics
  33. Lymphatic filariasis in Fiji: progress towards elimination, 1997–2007
  34. Risk factors for lymphatic filariasis and mass drug administration non-participation in Mandalay Region, Myanmar
  35. Primaquine alternative dosing schedules for preventing malaria relapse in people withPlasmodium vivax
  36. Lymphatic Filariasis Epidemiology in Samoa in 2018: Geographic Clustering and Higher Antigen Prevalence in Older Age Groups
  37. An assessment of coverage and adverse events following country-wide triple-therapy mass drug administration for lymphatic filariasis elimination, Samoa 2018
  38. Potential strategies for strengthening surveillance of lymphatic filariasis in American Samoa after mass drug administration: targeting older age groups, hotspots, and household members of infected persons
  39. Demographic, socioeconomic and disease knowledge factors, but not population mobility, associated with lymphatic filariasis infection in adult workers in American Samoa in 2014
  40. Genomic Epidemiology in Filarial Nematodes: Transforming the Basis for Elimination Program Decisions
  41. Lymphatic Filariasis in 2016 in American Samoa: Identifying Clustering and Hotspots Using Non-Spatial and Three Spatial Analytical Methods
  42. Burden of hydrocoele assessed from medical and surgical records in a lymphatic filariasis endemic country, Samoa
  43. Primaquine at alternative dosing schedules for preventing relapse in people withPlasmodium vivaxmalaria
  44. Elimination of lymphatic filariasis as a public health problem in Niue under PacELF, 1999–2016
  45. Investigation of Mixture Modelling Algorithms as a Tool for Determining the Statistical Likelihood of Serological Exposure to Filariasis Utilizing Historical Data from the Lymphatic Filariasis Surveillance Program in Vanuatu
  46. Preventive chemotherapy reverses covert, lymphatic‐associated tissue change in young people with lymphatic filariasis in Myanmar
  47. Large expert-curated database for benchmarking document
  48. GEOFIL: A spatially-explicit agent-based modelling framework for predicting the long-term transmission dynamics of lymphatic filariasis in American Samoa
  49. Combining different diagnostic studies of lymphatic filariasis for risk mapping in Papua New Guinea: a predictive model from microfilaraemia and antigenaemia prevalence surveys
  50. The prevalence of lymphatic filariasis infection and disease following six rounds of mass drug administration in Mandalay Region, Myanmar
  51. Identifying residual transmission of lymphatic filariasis after mass drug administration: Comparing school-based versus community-based surveillance - American Samoa, 2016
  52. The epidemiology of tuberculosis in the rural Balimo region of Papua New Guinea
  53. Gametocytocidal drugs: taking the population perspective
  54. The extensive networks of frequent population mobility in the Samoan Islands and their implications for infectious disease transmission
  55. Neglected and Emerging Tropical Diseases in South and Southeast Asia and Northern Australia
  56. Moderating Factors in Tissue Tonometry and Bioimpedance Spectroscopy Measures in the Lower Extremity of Healthy Young People in Australia and Myanmar
  57. Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission
  58. Expanding the Vector Control Toolbox for Malaria Elimination: A Systematic Review of the Evidence
  59. A Synthetic Population for Modelling the Dynamics of Infectious Disease Transmission in American Samoa
  60. Overview of PacELF—the Pacific Programme for the Elimination of Lymphatic Filariasis
  61. Lymphatic Filariasis Increases Tissue Compressibility and Extracellular Fluid in Lower Limbs of Asymptomatic Young People in Central Myanmar
  62. Detecting and confirming residual hotspots of lymphatic filariasis transmission in American Samoa 8 years after stopping mass drug administration
  63. Safety of primaquine given to people with G6PD deficiency: systematic review of prospective studies
  64. Prevalence and risk factors associated with lymphatic filariasis in American Samoa after mass drug administration
  65. Lymphatic Filariasis in Mainland Southeast Asia: A Systematic Review and Meta-Analysis of Prevalence and Disease Burden
  66. Surveillance efforts after mass drug administration to validate elimination of lymphatic filariasis as a public health problem in Vanuatu
  67. Impact of the Lymphatic Filariasis Control Program towards elimination of filariasis in Vanuatu, 1997–2006
  68. Identification and control of an isolated, but intense focus of lymphatic filariasis on Satawal Island, Federated States of Micronesia, in 2003
  69. Primaquine at alternative dosing schedules for preventing relapse in people withPlasmodium vivaxmalaria
  70. Relative Performance and Predictive Values of Plasma and Dried Blood Spots with Filter Paper Sampling Techniques and Dilutions of the Lymphatic Filariasis Og4C3 Antigen ELISA for Samples from Myanmar
  71. Concordance between Plasma and Filter Paper Sampling Techniques for the Lymphatic Filariasis Bm14 Antibody ELISA
  72. Intrarater Reliability of Tonometry and Bioimpedance Spectroscopy to Measure Tissue Compressibility and Extracellular Fluid in the Legs of Healthy Young People in Australia and Myanmar
  73. Lymphatic Filariasis Elimination in American Samoa: Evaluation of Molecular Xenomonitoring as a Surveillance Tool in the Endgame
  74. The prevalence of leprosy in school-students and evaluation of school-based screening for leprosy: A Systematic Review
  75. Self-Care for Management of Secondary Lymphedema: A Systematic Review
  76. Current WHO protocols for mass drug administration in helminth control
  77. Lymphatic Filariasis in Oceania
  78. Clinical case estimates of lymphatic filariasis in an endemic district of Bangladesh after a decade of mass drug administration
  79. Determinants of Bed Net Use in Southeast Nigeria following Mass Distribution of LLINs: Implications for Social Behavior Change Interventions
  80. Surgical Treatment of Genital Manifestations of Lymphatic Filariasis: A Systematic Review
  81. Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of seventh biannual meeting (March 2015)
  82. Evaluation of traps and lures for mosquito vectors and xenomonitoring of Wuchereria bancrofti infection in a high prevalence Samoan Village
  83. Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of sixth biannual meeting (September 2014)
  84. Primaquine or other 8-aminoquinoline for reducingPlasmodium falciparumtransmission
  85. Seroepidemiology of melioidosis in children from a remote region of Papua New Guinea
  86. Seroprevalence and Spatial Epidemiology of Lymphatic Filariasis in American Samoa after Successful Mass Drug Administration
  87. Primaquine or other 8-aminoquinoline for reducingP. falciparumtransmission
  88. Safety of 8-aminoquinolines given to people with G6PD deficiency: protocol for systematic review of prospective studies
  89. Malaria prevalence, anemia and baseline intervention coverage prior to mass net distributions in Abia and Plateau States, Nigeria
  90. A preliminary investigation of serological tools for the detection of Onchocerca lupi infection in dogs
  91. Estimation of insecticide persistence, biological activity and mosquito resistance to PermaNet® 2 long-lasting insecticidal nets over three to 32 months of use in Ethiopia
  92. Risk factors for anemia in children under 6 years of age in Ethiopia: analysis of the data from the cross-sectional Malaria IndicatorSurvey, 2007
  93. Community-Wide Distribution of Long-Lasting Insecticidal Nets Can Halt Transmission of Lymphatic Filariasis in Southeastern Nigeria
  94. Physical durability of PermaNet 2.0 long-lasting insecticidal nets over three to 32 months of use in Ethiopia
  95. Lymphatic filariasis in Papua New Guinea: distribution at district level and impact of mass drug administration, 1980 to 2011
  96. Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of September 2013 meeting
  97. Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of March 2013 meeting
  98. Primaquine for reducingPlasmodium falciparumtransmission
  99. Mosquito Feeding Assays to Determine the Infectiousness of Naturally Infected Plasmodium falciparum Gametocyte Carriers
  100. Evidence for Stopping Mass Drug Administration for Lymphatic Filariasis in Some, But Not All Local Government Areas of Plateau and Nasarawa States, Nigeria
  101. Performance of Local Light Microscopy and the ParaScreen Pan/Pf Rapid Diagnostic Test to Detect Malaria in Health Centers in Northwest Ethiopia
  102. Lymphatic filariasis in western Ethiopia with special emphasis on prevalence of Wuchereria bancrofti antigenaemia in and around onchocerciasis endemic areas
  103. Analysis of malaria surveillance data in Ethiopia: what can be learned from the Integrated Disease Surveillance and Response System?
  104. Inaugural meeting of the malaria policy advisory committee to the WHO: conclusions and recommendations
  105. Factors associated with mosquito net use by individuals in households owning nets in Ethiopia
  106. Malaria, Oromia Regional State, Ethiopia, 2001-2006
  107. Which nets are being used: factors associated with mosquito net use in Amhara, Oromia and Southern Nations, Nationalities and Peoples' Regions of Ethiopia
  108. Oral vaccines for preventing cholera
  109. Vaccines for preventing cholera: killed whole cell or other subunit vaccines (injected)
  110. Knowledge of Malaria and Its Association with Malaria-Related Behaviors—Results from the Malaria Indicator Survey, Ethiopia, 2007
  111. Oral vaccines for preventing cholera
  112. Comparison of Parascreen Pan/Pf, Paracheck Pf and light microscopy for detection of malaria among febrile patients, Northwest Ethiopia
  113. Rapid Increase in Ownership and Use of Long-Lasting Insecticidal Nets and Decrease in Prevalence of Malaria in Three Regional States of Ethiopia (2006-2007)
  114. Malaria indicator survey 2007, Ethiopia: coverage and use of major malaria prevention and control interventions
  115. Individual, household and environmental risk factors for malaria infection in Amhara, Oromia and SNNP regions of Ethiopia
  116. Primaquine for reducing transmission of Plasmodium falciparum malaria
  117. Systematic Reviews in Malaria: Global Policies Need Global Reviews
  118. Malaria prevalence and mosquito net coverage in Oromia and SNNPR regions of Ethiopia
  119. Risk factors for active trachoma in children and trichiasis in adults: a household survey in Amhara Regional State, Ethiopia
  120. Integrating an NTD with One of “The Big Three”: Combined Malaria and Trachoma Survey in Amhara Region of Ethiopia
  121. Effectiveness of malaria control during changing climate conditions in Eritrea, 1998-2003
  122. Evaluation of light microscopy and rapid diagnostic test for the detection of malaria under operational field conditions: a household survey in Ethiopia
  123. Malaria Stratification, Climate, and Epidemic Early Warning in Eritrea
  124. Productivity of natural and artificial containers for Aedes polynesiensis and Aedes aegypti in four American Samoan villages
  125. Wuchereria bancrofti Filariasis Control in Samoa before PacELF (Pacific Programme to Eliminate Lymphatic Filariasis)
  126. Lymphatic filariasis elimination in the Pacific: PacELF replicating Japanese success
  127. Vaccines for preventing malaria (blood-stage)
  128. Vaccines for preventing malaria (pre-erythrocytic)
  129. Battling Malaria
  130. Vaccines for preventing malaria (SPf66)
  131. MALARIA PREVALENCE AND ASSOCIATED RISK FACTORS IN ERITREA
  132. The Benefits of Artemisinin Combination Therapy for Malaria Extend Beyond the Individual Patient
  133. IMPREGNATED NETS OR DDT RESIDUAL SPRAYING? FIELD EFFECTIVENESS OF MALARIA PREVENTION TECHNIQUES IN SOLOMON ISLANDS, 1993–1999
  134. Malaria, Babesiosis, Theileriosis and Related Diseases
  135. Impregnated Nets Cannot Fully Substitute for DDT: Field Effectiveness of Malaria Prevention in Solomon Islands
  136. Vaccines for preventing malaria
  137. Vaccines for preventing malaria
  138. Prospective study of enteroviral infections and development of beta-cell autoimmunity
  139. Vaccines for preventing cholera
  140. Malaria, Babesiosis, Theileriosis and Related Diseases
  141. Lack of association between early childhood immunizations and beta-cell autoimmunity
  142. Pathogenesis, prediction and trials for the prevention of insulin-dependent (type 1) diabetes mellitus1Abbreviations: s.c., subcutaneous; i.p., intraperitoneal; i.v., intravenous; IFA, incomplete Freund's adjuvant; DTP, diphtheria-tetanus-pertussis; LC...
  143. Prevention of Type 1 Diabetes from Laboratory to Public Health
  144. The SPf66 Malaria Vaccine: What is the Evidence for Efficacy?
  145. Comparison of the cost-effectiveness of vaccines and insecticide impregnation of mosquito nets for the prevention of malaria
  146. Vaccines for preventing tick-borne encephalitis
  147. Vaccines for preventing anthrax
  148. Vaccines for preventing anthrax
  149. The role of enteroviral infections in the development of IDDM: limitations of current approaches
  150. The Role of Enteroviral Infections in the Development of IDDM: Limitations of Current Approaches
  151. Mortality From Intentional and Unintentional Injury Among Infants of Young Mothers in Colorado, 1986 to 1992
  152. The value of vector-based estimates of malaria transmission
  153. Human Malaria Transmission: Reconciling Field and Laboratory Data
  154. Human Antibody Responses to Epitopes on the Plasmodium Falciparum Gametocyte Antigen PFS 48/45 and their Relationship to Infectivity of Gametocyte Carriers
  155. Malaria Vaccines
  156. Conserved and Variant Epitopes of Target Antigens of Transmission-Blocking Antibodies among Isolates of Plasmodium falciparum from Malaysia
  157. Antibody responses to Plasmodium falciparum gametocyte antigens during and after malaria attacks in schoolchildren from Madang, Papua New Guinea
  158. Refractoriness of erythrocytes infected with Plasmodium falciparum gametocytes to lysis by sorbitol
  159. Properties of epitopes of Pfs 48/45, a target of transmission blocking monoclonal antibodies, on gametes of different isolates of Plasmodium falciparum
  160. Variations in Malaria Transmission Rates are not Related to Anopheline Survivorship per Feeding Cycle
  161. The primary antibody response of malaria patients to Plasmodium falciparum sexual stage antigens which are potential transmission blocking vaccine candidates
  162. The prevalence of naturally acquired multiple infections of Wuchereria bancrofti and human malarias in anophelines
  163. High Frequency of Antibody Response to Plasmodium falciparum Gametocyte Antigens during Acute Malaria Infections in Papua New Guinea Highlanders
  164. Human immune response directed against Plasmodium falciparum heat shock-related proteins
  165. Estimation of Anopheline Survival Rate, Vectorial Capacity and Mosquito Infection Probability from Malaria Vector Infection Rates in Villages Near Madang, Papua New Guinea
  166. A Cyclical Feeding Model for Pathogen Transmission and Its Application to Determine Vectorial Capacity from Vector Infection Rates
  167. Sequence coding for a sexual stage specific protein of Plasmodium falciparum
  168. Sequence coding for a sexual stage specific protein ofPlasmodium falciparum
  169. Plasmodium falciparum: An abundant stage-specific protein expressed during early gametocyte development
  170. Human host selection by anophelines: no evidence for preferential selection of malaria or microfilariae-infected individuals in a hyperendemic area
  171. Differential antibody responses to Plasmodium falciparum and P. vivax circumsporozoite proteins in a human population
  172. An Analysis of some Factors Determining the Sporozoite Rates, Human Blood Indexes, and Biting Rates of Members of the Anopheles punctulatus Complex in Papua New Guinea
  173. Restricted or absent immune responses in human populations to Plasmodium falciparum gamete antigens that are targets of malaria transmission-blocking antibodies
  174. Naturally occurring antibodies to an epitope on Plasmodium falciparum gametes detected by monoclonal antibody-based competitive enzyme-linked immunosorbent assay
  175. Human Malaria Transmission Studies in the Anopheles Punctulatus Complex in Papua New Guinea: Sporozoite Rates, Inoculation Rates, and Sporozoite Densities
  176. Mixed Blood Feeding by the Malaria Vectors in the Anopheles punctulatus Complex (Diptera: Culicidae)
  177. Evidence for a ‘memorized’ home range in Anopheles farauti females from Papua New Guinea
  178. Measurement of malarial infectivity of human populations to mosquitoes in the Madang area, Papua New Guinea
  179. Antibodies to Plasmodium falciparum gamete surface antigens in Papua New Guinea sera
  180. Immunity to Sexual Stages of Malaria Parasites
  181. The effect of permethrin-impregnated bednets on a population of Anopheles farauti in coastal Papua New Guinea
  182. Field Evaluation of Enzyme-linked Immunosorbent Assays for Plasmodium falciparum and Plasmodium vivax Sporozoites in Mosquitoes (Diptera: Culicidae) from Papua New Guinea1
  183. Factors Influencing Invasion of Erythrocytes by Plasmodium falciparum Parasites: The Effects of an N-Acetyl Glucosamine Neoglycoprotein and an Anti-Glycophorin a Antibody
  184. Capture-recapture studies with mosquitoes of the group of Anopheles punctulatus Dönitz (Diptera: Culicidae) from Papua New Guinea
  185. Two apparently nonrepeated epitopes on gametes of Plasmodium falciparum are targets of transmission-blocking antibodies
  186. Effects of transmission-blocking monoclonal antibodies on different isolates of Plasmodium falciparum
  187. Target Antigens in Malaria Transmission Blocking Immunity
  188. Mechanism of pyrimethamine resistance in recent isolates of Plasmodium falciparum.
  189. Gametocyte Production in Cloned Lines of Plasmodium Falciparum
  190. First Field Trial of an Immunoradiometric Assay for the Detection of Malaria Sporozoites in Mosquitoes
  191. Drug Sensitivity and Isoenzyme Type in Cloned Lines of Plasmodium Falciparum
  192. Plasmodium falciparum: Effect of time in continuous culture on binding to human endothelial cells and amelanotic melanoma cells
  193. Target antigens of transmission-blocking immunity on gametes of plasmodium falciparum
  194. Susceptibility ofAnopheles gambiaetoPlasmodium yoelii nigeriensisandPlasmodium falciparum
  195. A Cage Replacement Experiment Involving Introduction of Genes for Refractoriness to Plasmodium Yoelii Nigeriensis into a Population of Anopheles Gambiae (Diptera: Culicidae)
  196. Studies on the use of a membrane feeding technique for infecting Anopheles gambiae with Plasmodium falciparum
  197. Immunity to Sexual Stages of Malaria Parasites